^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | cisplatin (DNA synthesis inhibitor) + pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
09/01/2021
Excerpt:
Although the most frequently studied regimen is cisplatin-vinorelbine, other combinations such as cisplatin and gemcitabine, or docetaxel or pemetrexed (only in adenocarcinoma tumours) could be also feasible [II, B].
